Key Points
- Insider selling: Chief commercial officer Kevin Patrick Danahy sold a total of 85,000 Pulse Biosciences shares in multiple February transactions (about $2.0 million), including a 5,000‑share sale on Feb. 18 at $23.64, trimming his stake by 10.35% to 43,298 shares (≈$1.02M).
- Q4 results showed EPS of ($0.26), beating the consensus (−$0.32), while reported revenue was (−$0.09) million versus expectations of $0.23 million.
- Analysts are mixed: the consensus rating is Hold with an average target price of $30, though individual ratings range from Sell to Outperform.
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) insider Kevin Patrick Danahy sold 5,000 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total value of $118,200.00. Following the sale, the insider owned 43,298 shares in the company, valued at $1,023,564.72. The trade was a 10.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Kevin Patrick Danahy also recently made the following trade(s):
- On Friday, February 13th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00.
- On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.63, for a total transaction of $472,600.00.
- On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $429,000.00.
- On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00.
Pulse Biosciences Price Performance
Shares of PLSE opened at $20.19 on Tuesday. The firm has a market capitalization of $1.37 billion, a PE ratio of -18.69 and a beta of 1.77. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $26.30. The company's fifty day moving average price is $16.47 and its 200-day moving average price is $16.13.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.06. The firm had revenue of ($0.09) million during the quarter, compared to analysts' expectations of $0.23 million.
Analysts Set New Price Targets
A number of equities research analysts recently commented on PLSE shares. Wall Street Zen upgraded Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday. Finally, Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of "Hold" and an average target price of $30.00.
View Our Latest Stock Analysis on Pulse Biosciences
Institutional Investors Weigh In On Pulse Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Portolan Capital Management LLC purchased a new position in shares of Pulse Biosciences during the 3rd quarter valued at approximately $1,809,000. Brooklyn Investment Group grew its position in Pulse Biosciences by 330.7% during the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company's stock valued at $1,844,000 after buying an additional 100,081 shares during the period. Geode Capital Management LLC grew its position in Pulse Biosciences by 7.2% during the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company's stock valued at $7,538,000 after buying an additional 33,744 shares during the period. XTX Topco Ltd purchased a new position in Pulse Biosciences in the second quarter valued at $466,000. Finally, Argo Wealth Advisory LLC acquired a new position in shares of Pulse Biosciences in the fourth quarter worth about $387,000. Institutional investors and hedge funds own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
